share_log

B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5

B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5

Bof A Securities将Achilles Therapeutics的评级下调至表现不佳,将目标股价下调至0.5美元
Benzinga ·  2023/12/14 07:18

B of A Securities analyst Tazeen Ahmad downgrades Achilles Therapeutics (NASDAQ:ACHL) from Buy to Underperform and lowers the price target from $7 to $0.5.

B of A Securities分析师塔泽恩·艾哈迈德将Achilles Therapeutics(纳斯达克股票代码:ACHL)的评级从买入下调至表现不佳,并将目标股价从7美元下调至0.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发